Qiagen and Illumina sign 15-year deal for IVD tests

9 October 2019 (Last Updated October 9th, 2019 12:00)

Diagnostic solutions providers Qiagen and Illumina have collaborated to boost the availability and use of next-generation sequencing (NGS)-based in-vitro diagnostic (IVD) tests, including companion diagnostics, for clinical patient management.

Qiagen and Illumina sign 15-year deal for IVD tests
Scientists working on the development of companion diagnostics at Qiagen’s research and development laboratory in Manchester, UK. Credit: QIAGEN.

Diagnostic solutions providers Qiagen and Illumina have collaborated to boost the availability and use of next-generation sequencing (NGS)-based in-vitro diagnostic (IVD) tests, including companion diagnostics, for clinical patient management.

Under the 15-year alliance, Qiagen will receive non-exclusive rights for the development and worldwide commercialisation of IVD kits for use alongside Illumina’s MiSeq Dx and NextSeq 550Dx Systems.

The deal also covers rights to expand the collaboration to include future Illumina diagnostic systems.

Furthermore, Qiagen may develop companion diagnostics leveraging Illumina’s TruSight Oncology (TSO) assays, which analyse tumour samples for comprehensive genomic profiling in immunotherapy.

The companies will work together to commercialise a range of clinically validated workflows combining Qiagen’s content and bioinformatics solutions.

Initially, Qiagen and Illumina will commercialise IVD kits meant for management of cancer patients.

The collaboration may expand to other clinical diagnostic areas, including infectious diseases, cardiology, inflammatory and autoimmune diseases, as well as hereditary disorders.

Illumina CEO Francis deSouza said: “We are committed to expanding the range of clinical use cases addressed by genomic sequencing by enabling partners to deliver IVD tests and companion diagnostics on Illumina’s Dx instruments.

“Our partnership with Qiagen will complement Illumina’s TSO 500 family with additional testing menu options, accelerating NGS adoption in oncology patient management.”

Qiagen intends to use its companion diagnostic capabilities and Sample to Insight solutions to create a menu of IVD tests on Illumina’s Dx sequencers to bolster channel reach and the IVD market presence of both the companies.

Qiagen CEO Peer Schatz said: “Through this partnership, we look forward to creating significant benefits for customers and for both parties, as well as to allowing Qiagen to maximise our opportunities as a company creating value by offering sample-to-insight solutions.”